PACE | Pathways to Antimicrobial Clinical Efficacy

Advancing small-molecule drug leads to inhibit a crucial enzyme in ‘Enterobacterales’ bacteria

‘Enterobacterales’ gram-negative bacteria cause some of the most severe bacterial infections in hospitals





But many of these bacteria are resistant to existing antibiotics

Arrepath is developing a series of compounds that inhibit an essential enzyme in gram-negative bacteria that has never been targeted before



Arrepath’s novel AI/machine learning platform can test millions of different compounds for antibacterial activity



Arrepath’s lead inhibitors are highly potent against Enterobacterales, disrupting enzyme activity and killing the bacteria, without killing human cells



PACE

With funding and support from PACE, Arrepath will

- Optimise inhibitor properties
- Demonstrate effectiveness against *E.coli* and additional Enterobacterales species

Success will enable Arrepath to advance the development of new antibiotics for treating the most severe bacterial infections in both intravenous and oral pill formats, to support patients’ needs



ARREPATH